Published in Clin Cancer Res on September 25, 2012
Multiple Myeloma Molecular Monitoring Study (M4) | NCT03421132
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci (2013) 1.25
Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One (2013) 1.08
Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res (2013) 0.94
Translating metastasis-related biomarkers to the clinic--progress and pitfalls. Nat Rev Clin Oncol (2013) 0.88
Circulating free DNA in the management of breast cancer. Ann Transl Med (2014) 0.85
Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients. Genes Chromosomes Cancer (2013) 0.85
Cell-free circulating tumor DNA in cancer. Chin J Cancer (2016) 0.85
Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? Expert Rev Mol Diagn (2015) 0.84
Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? Nat Rev Clin Oncol (2016) 0.84
Partial PTEN deletion is linked to poor prognosis in breast cancer. BMC Cancer (2015) 0.78
Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl Lung Cancer Res (2016) 0.78
Aberrant reduction of telomere repetitive sequences in plasma cell-free DNA for early breast cancer detection. Oncotarget (2015) 0.76
Detection of BRAF mutation in the cytocentrifugation supernatant fluid from fine-needle aspiration of thyroid lesions may enhance the diagnostic yield. Cytojournal (2017) 0.75
The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center. BMC Gastroenterol (2014) 0.75
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol (2013) 4.28
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Circulating tumor cells: liquid biopsy of cancer. Clin Chem (2012) 3.87
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res (2010) 2.98
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer (2005) 2.74
Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer (2008) 2.72
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Circulating tumor cells and circulating tumor DNA. Annu Rev Med (2011) 2.16
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat (2010) 2.12
Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res (2005) 2.10
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res (2008) 2.06
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev (2013) 1.82
Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res (2012) 1.79
Cancer micrometastasis and tumour dormancy. APMIS (2008) 1.78
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A (2011) 1.71
Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res (2012) 1.63
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (2013) 1.62
Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst (2005) 1.60
Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res (2011) 1.58
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res (2011) 1.56
Biologic challenges in the detection of circulating tumor cells. Cancer Res (2012) 1.55
Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem (2012) 1.53
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res (2003) 1.53
Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res (2006) 1.52
[Hemangiosarcoma after breast-conserving therapy of breast cancer: report of four cases with molecular genetic diagnosis and literature review]. Strahlenther Onkol (2011) 1.51
Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies. Onkologie (2009) 1.51
Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res (2003) 1.51
Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res (2009) 1.50
Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther (2007) 1.50
Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev (2012) 1.47
Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology (2008) 1.47
Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res (2006) 1.46
Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res (2004) 1.40
Clinical relevance and biology of circulating tumor cells. Breast Cancer Res (2011) 1.34
Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res (2004) 1.33
Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res (2004) 1.31
Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res (2012) 1.30
Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res (2013) 1.29
Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem (2007) 1.28
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer (2013) 1.27
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer (2011) 1.27
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J (2011) 1.25
Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res (2009) 1.25
High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer (2003) 1.25
Technologies for detection of circulating tumor cells: facts and vision. Lab Chip (2013) 1.24
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res (2006) 1.24
Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer (2013) 1.23
Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol Immunother (2013) 1.23
The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res (2012) 1.22
Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol (2011) 1.22
Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int (2010) 1.22
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res (2012) 1.21
Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol (2011) 1.21
Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res (2012) 1.20
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol (2013) 1.19
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood (2013) 1.19
Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res (2009) 1.19
Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res (2010) 1.18
Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci (2008) 1.17
Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol (2012) 1.16
Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat (2012) 1.16
Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One (2013) 1.16
Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat (2010) 1.15
Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann N Y Acad Sci (2010) 1.15
Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A (2002) 1.15
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. J Immunol Methods (2005) 1.13
Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer. Cancer Res (2009) 1.12
Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol (2003) 1.11
The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat (2012) 1.11